The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Impact of delaying pegaspargase during induction on hepatotoxicity in adult patients with ALL
|
Pegaspargase-associated high-grade hepatoxicity occurs in 24–50% of adult patients with ALL, with incidences increasing with older age, obesity, and higher doses.1 Delaying pegaspargase dosing during induction was hypothesized to improve the hepatoxicity profile. A retrospective analysis assessed the impact of early pegaspargase (Day 4 ± 2; EP) vs delayed pegaspargase (Day 15 ± 2; DP) dosing during induction in 141 adult patients with ND ALL.1 Results from this analysis were published in the British Journal of Haematology by Tinajero, et al.1 |
| Key learnings |
|
Patients who received EP had a numerically higher incidence of Grade ≥3 hepatotoxicity compared with patients who received DP, although this did not reach statistical significance (34.6% vs 19%; p = 0.06). |
| Clinical efficacy outcomes were similar between patients who received EP vs DP, including CR/CRi rates (89.7% vs 79.4%; p = 0.13), MRD-negativity rates (61.4% vs 58%; p = 1), OS (p = 0.59), and EFS (HR, 0.70; 95% CI, 0.39–1.26). |
| More patients who received EP required post-pegaspargase chemotherapy dose modifications during induction compared with patients who received DP (23.1% vs 4.8%; p <0.01). |
| Results suggest that delaying pegaspargase during induction may reduce hepatoxicity and maintain chemotherapy dose intensity without negatively impacting efficacy outcomes in adult patients with ALL. |
Abbreviations: ALL, acute lymphoblastic leukemia; CI, confidence interval; CR, complete remission; CRi, complete remission with incomplete count recovery; DP, delayed pegaspargase; EFS, event-free survival; EP, early pegaspargase; ND, newly diagnosed; MRD, measurable residual disease; OS, overall survival.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?
